Radiolabeled monoclonal antibodies can specifically bind to tumor-associated antigens.On this immune basis,RIT and RII have therefore been used in the diagnosis and treatment of cancer.Many RIT and RII pharmaceuticals were applied in trials of preclinical and clinical phases,and excellent results had been achieved.This paper reviews on the current status of RIT and RII pharmaceuticals.
Result Analysis
Print
Save
E-mail